Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday

Precision BioSciences (NASDAQ:DTIL) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $9.0750 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL opened at $6.52 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 13.32 and a quick ratio of 13.32. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $8.82. The company has a market cap of $161.24 million, a P/E ratio of -1.27 and a beta of 1.28. The stock’s fifty day moving average price is $4.48 and its 200-day moving average price is $5.06.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DTIL. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $19.00 price target on shares of Precision BioSciences in a research note on Friday, March 13th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $39.50.

Insider Activity at Precision BioSciences

In related news, CEO Michael Amoroso sold 20,559 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $78,946.56. Following the completion of the sale, the chief executive officer owned 243,392 shares in the company, valued at approximately $934,625.28. This represents a 7.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO John Alexander Kelly sold 8,149 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $31,292.16. Following the completion of the transaction, the chief financial officer directly owned 125,883 shares in the company, valued at approximately $483,390.72. This represents a 6.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 93,845 shares of company stock worth $376,677. 4.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd increased its holdings in Precision BioSciences by 344.7% during the fourth quarter. Quadrature Capital Ltd now owns 62,129 shares of the company’s stock valued at $258,000 after buying an additional 48,158 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Precision BioSciences during the 4th quarter worth $167,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Precision BioSciences during the 4th quarter worth $253,000. Marshall Wace LLP bought a new stake in shares of Precision BioSciences during the 4th quarter valued at $295,000. Finally, Quarry LP grew its position in shares of Precision BioSciences by 15.1% during the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock valued at $284,000 after acquiring an additional 8,936 shares during the period. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.